Kane Logo Cropped TransBG.png
Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow
22 août 2024 16h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will announce its second quarter 2024 financial results after market close on...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
22 août 2024 08h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution...
Kane Logo Cropped TransBG.png
Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family
13 août 2024 08h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to...
Kane Logo Cropped TransBG.png
Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
23 juil. 2024 08h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA)...
Kane Logo Cropped TransBG.png
Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification
17 juil. 2024 08h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, July 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has received ISO 13485:2016 Medical Device Single Audit...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Issuance of Restricted Share Units
15 juil. 2024 08h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, July 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 4,213,133 restricted share...
Kane Logo Cropped TransBG.png
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.
11 juil. 2024 08h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, July 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed a worldwide license agreement with...
Kane Logo Cropped TransBG.png
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
27 juin 2024 08h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of...
Kane Logo Cropped TransBG.png
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
25 juin 2024 08h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, June 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has entered into a worldwide license agreement with...
Kane Logo Cropped TransBG.png
Kane Biotech Announces First Quarter 2024 Financial Results
23 mai 2024 16h15 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results. The...